Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Junji FuruseMakoto UenoMasafumi IkedaTakuji OkusakaZhaoyang TengMomoko FuruyaTatsuya IokaPublished in: Japanese journal of clinical oncology (2022)
We explored safety profile of nal-IRI combination regimen recognized as effective and tolerable treatment for Japanese unresectable pancreatic cancer patients. Although the treatment-emergent adverse events occurred were controllable, patients with prolonged toxicities should be closely managed.